Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Testicular cancer

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Tension-type headache

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Motile ciliopathies

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Gestational diabetes mellitus

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Invasive candidiasis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Antiphospholipid syndrome

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Liang Cheng
  • Peter Albers
  • Daniel M Berney
  • Darren R Feldman
  • Gedske Daugaard
  • Timothy Gilligan
  • Leendert H J Looijenga
Vis graf over relationer

Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.

OriginalsprogEngelsk
TidsskriftNature reviews. Disease primers
Vol/bind4
Udgave nummer1
Sider (fra-til)29
ISSN2056-676X
DOI
StatusUdgivet - 5 okt. 2018

ID: 55865158